IDEAYA Director Gets 20,000 Stock Options at $21.78 Strike Price

IDEAYA Biosciences (IDYA) director Terry J. Rosen received a stock option grant on June 24, 2025.

Rhea-AI Filing Summary

IDEAYA Biosciences (IDYA) director Terry J. Rosen received a stock option grant on June 24, 2025. The key details of this insider transaction include:

• Granted 20,000 stock options to purchase common stock at an exercise price of $21.78 per share
• Options will expire on June 24, 2035
• Vesting schedule: 100% vests on the earlier of: - First anniversary of grant date - Immediately before next Annual Meeting
• Vesting is contingent on continued board service

This grant represents standard non-employee director compensation and aligns the director's interests with shareholders through long-term equity ownership. The filing was submitted via attorney-in-fact Andres Ruiz Briseno on June 26, 2025.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider ROSEN TERRY J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did IDYA director Terry Rosen receive on June 24, 2025?

Terry Rosen received 20,000 stock options with an exercise price of $21.78 per share. These options were granted on June 24, 2025, and will expire on June 24, 2035.

What are the vesting terms for Terry Rosen's IDYA stock options granted in June 2025?

The stock options will vest 100% on the earlier of: (i) the first anniversary of the grant date (June 24, 2026) or (ii) immediately prior to the next Annual Meeting following the grant date. Vesting is subject to Rosen continuing to serve on IDYA's Board through the vesting date.

Who is Terry Rosen at IDYA and what is their role?

Terry J. Rosen serves as a Director on the Board of IDEAYA Biosciences, Inc. (IDYA). This is confirmed by the Form 4 filing which indicates Rosen's relationship to the issuer as 'Director' with an 'X' marked in the corresponding box.

What is the total value of IDYA stock options granted to Terry Rosen in this Form 4?

The Form 4 shows Terry Rosen was granted 20,000 stock options with an exercise price of $21.78 per share. The options were granted at $0 cost to Rosen, as indicated in the 'Price of Derivative Security' column, representing standard compensation for board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2025 - 04:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSEN TERRY J

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.78	06/24/2025		A		20,000		(1)	06/24/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

	/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Terry J. Rosen	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.